162636 rp graphics text

Massachusetts General HospitalPsychiatry AcademyMGHCME.org

PSYCHOPHARMACOLOGY

Jerrold F. Rosenbaum, MDPsychiatrist-in-ChiefMassachusetts General HospitalStanley Cobb Professor of PsychiatryHarvard Medical School

COURSE DIRECTORS:

THURSDAY-SUNDAY, OCTOBER 22-25, 2015Westin Copley Place • 10 Huntington Ave., Boston, MA

Maurizio Fava, MDDirector, Division of Clinical Research of the MGH Research InstituteExecutive Vice Chair, Department of PsychiatryExecutive Director, MGH Clinical Trials Network and InstituteMassachusetts General HospitalSlater Family Professor of PsychiatryHarvard Medical School


WELCOME

Welcome to the Massachusetts General Hospital Psychiatry Academy’s 39th AnnualPsychopharmacology Course.

This course highlights the latest research findings in psychopharmacology and their clinical applicationsacross the spectrum of psychiatric disorders, including, anxiety, ADHD, depression, bipolar disorder, eatingdisorders, OCD, psychosis, PTSD, substance abuse, and more.

TARGET AUDIENCE

This program is intended for psychiatrists, primary care and family practice physicians, psychologists, nursing professionals, andsocial workers.

COMPLIMENTARY BREAKFAST AND COFFEE BREAKS

Complimentary breakfast and coffee breaks will be available to course participants. Please note: lunch and dinner are notprovided and are on your own.

EVALUATION FORMS/CME/CEU CERTIFICATES

Every participant needs to complete the activity evaluation online to claim CME/CEU credits for this course. Please refer to theEvaluation and CME Information document in this syllabus for more information. We strongly encourage you to complete theevaluation, even if you do not require a certificate. Your comments are important to us as we plan future programs. The link toclaim credit is as follows: www.mghcme.org/psychopharm

QUESTIONS

Opportunity for questions will be provided at the end of each module during the panel discussion. Please write your questionson the index cards provided. Cards will be collected during the last 15 minutes of the lecture prior to the start of the paneldiscussion. Experience has shown that this method is preferable to that of spontaneous questions.

COPYRIGHT

The course materials and PowerPoint presentations are copyright protected by Massachusetts General Hospital, Department ofPsychiatry, Division of Postgraduate Education, the faculty members and the appropriate authors. Videotaping and audiotapingare not allowed. Thank you for your cooperation.

CELLULAR TELEPHONES & PAGERS

During the lectures, we ask that you turn your cell phones and pagers to vibrate or off. We also ask that you do not talk on yourcell phones inside the meeting room. Thank you for your cooperation.

CONTACT INFORMATION

For questions or comments, please contact MGH Psychiatry Academy member services at 866-644-7792 or

[email protected]

PSYCHOPHARMACOLOGYThursday–sunday • OcTOber 22-25, 2015

WesTin cOpley place • 10 hunTin TOn a e , bOsTOn, Ma


LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to: Identify rational, evidence-based pharmacologic and non-pharmacologic therapies for patients with unipolar, bipolar,

treatment-resistant, and post-partum depression. Assess obstacles to maintenance of long-term recovery and the liability issues associated with psychopharmacology. Discuss diagnostic and evidenced-based treatment strategies for pediatric onset mood disorders. Compare the neurobiology and evidence-based treatment approaches to addiction, anxiety, schizophrenia, and mood

disorders. Review the course and treatment of psychiatric disorders during pregnancy and menopause. Recognize psychosocial issues and evidence-based treatment modalities for eating and sleep disorders. Analyze drug interactions and the pharmacotherapy of adult ADHD and geriatric disorders.

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of theAccreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital andMassachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education forphysicians.

McLean Hospital designates this live activity for a maximum of 31.25 AMA PRA Category 1 Credits™. Physicians should onlyclaim credit commensurate with the extent of their participation in the activity.

PSYCHOLOGISTS

The Massachusetts General Hospital Department of Psychiatry is approved by the American Psychological Association tosponsor continuing education (CE) for psychologists. The Massachusetts General Hospital Department of Psychiatry maintainsresponsibility for this program and its content. This offering meets the criteria for 31.25 Continuing Education (CE) credits forpsychologists.

REGISTERED NURSES

This program meets the requirements of the Massachusetts Board of Registration in Nursing (244 CMR 5.00) for 31.25 contacthours of nursing continuing education credit. Advance practice nurses, please note: Educational activities which meet therequirements of the ACCME (such as this activity) count towards 50% of the nursing requirement for ANCC accreditation.

SOCIAL WORKERS

This program has been approved for 30.5 Social Work Continuing Education hours for relicensure, in accordance with 258 CMR.Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D 71097.

RISK MANAGEMENT

(**Sessions qualify for risk management credit)

Physicians: 1.5 credits meet the criteria of the Massachusetts Board of Registration in Medicine for risk management study.

Other CE Licenses: Other Providers can claim a Participation Certificate upon successful completion of this course.Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1Credits™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMAPRA Category 1 Credits™ may or may not fulfill continuing education requirements. Providers should also consider savingcopies of brochures, agenda, and other supporting documents.


Thursday, October 22, 2015

4:00 – 8:00PM Neuromodulation 2015: State of the ArtTHIS IS A TICKETED EVENT, DINNER SERVED

Friday, October 23, 2015

7:00 – 8:00AM Registration &Continental Breakfast

8:00 – 8:15AM WelcomeMaurizio Fava, MD

8:15 – 8:30AM Introduction and OverviewJerrold F. Rosenbaum, MD

MODULE TOPIC – MOOD DISORDERS

8:30– 9:15AM Bipolar DepressionAndrew A. Nierenberg, MD

9:15 – 10:00AM Bipolar Long Term ManagementRoy H. Perlis, MD, MSc

Coffee Break10:00 – 10:15AM

10:15 – 11:00AM Treatment Resistant DepressionMaurizio Fava, MD

11:00 – 12:00PM Panel DiscussionModerator: Jerrold F. Rosenbaum, MDPanelists: Andrew A. Nierenberg, MD; Roy H. Perlis, MD, MSc; Maurizio Fava, MD

12:00 – 1:00PM Lunch (on your own)

MODULE TOPIC – ANXIETY/OCD

1:00 – 1:45PM OCDMichael A. Jenike, MD

1:45 – 2:30PM PTSDNaomi M. Simon, MD, MSc

2:30 – 3:15PM Anxiety Disorders and TreatmentsKerry J. Ressler, MD, PhD

3:15 – 3:30PM Coffee Break

3:30 – 4:15PM Obsessive-Compulsive Related DisordersLisa M. Zakhary, MD, PhD

AGENDA

Massachusetts General HospitalPsychiatry Academy MGHCME.org

4:15 – 5:00PM Panel DiscussionModerator: Michael A. Jenike, MDPanelists: Kerry J. Ressler, MD, PhD; Lisa M. Zakhary, MD, PhD;Naomi M. Simon, MD, MSc

5:00 – 6:30PM Dinner (on your own)

Friday, October 23, 2015: Evening Seminars

6:30 – 7:30PM Friday Evening Seminars (please pick two):7:30 – 8:30PM Seminars will begin at 6:30 PM and will repeat at 7:30 PM.

Natural Medications for Psychiatric DisordersAlbert S. Yeung, MD, ScD(Adams/Baltic, 7th Floor)

SuicideTheodore A. Stern, MD(St. George A-B, 3rd Floor)

The Neurobiology of AddictionJodi Gilman, PhD(St. George C, 3rd Floor)

Psychopharmacology of Sleep DisordersMatt T. Bianchi, MD, PhD, MMSc(America Ballroom, 4th Floor)

The Neurobiology of Mood and Psychotic DisordersDost Öngür, MD, PhD(Empire, 7th Floor)

Cognitive-Behavioral Therapy to Augment Psychopharmalogical TherapyMichael W. Otto, PhD(St. George D, 3rd Floor)


Saturday, October 24, 2015

7:00 – 8:00AM Continental Breakfast

8:00 – 8:10AM Welcoming RemarksDavid H. Rubin, MD

MODULE TOPIC – PSYCHOSIS

8:10 – 8:55AM First-Episode Psychosis and SchizophreniaOliver Freudenreich, MD, FAPM

8:55 – 9:30AM Drug InteractionsJonathan E. Alpert, MD, PhD

9:30 – 9:45AM Coffee Break

9:45 – 10:30AM Management of Side-Effects of AntipsychoticsDavid C. Henderson, MD

10:30 – 11:30AM Panel DiscussionModerator: David H. Rubin, MDPanelists: Oliver Freudenreich, MD, FAPM; David C. Henderson, MD;Jonathan E. Alpert, MD, PhD


MODULE TOPIC – NEW THERAPIES

12:30 – 1:30PM Stimulation and/or Surgical Approaches to Psychiatric IllnessDarin D. Dougherty, MD, MMSc

1:30 – 2:30PM New Treatments for Bipolar DisorderRoy H. Perlis, MD, MSc


2:45 – 3:45PM New Treatments for DepressionGeorge I. Papakostas, MD

3:45 – 4:30PM New AntipsychoticsDavid C. Henderson, MD

4:30 – 5:15PM Panel DiscussionModerator: David C. Henderson, MDPanelists: Roy H. Perlis, MD, MSc; George I. Papakostas, MD

5:15 – 6:30PM Dinner (on your own)


Saturday, October 24, 2015: Evening Seminars

6:30 – 7:30PM Saturday Evening Seminars (please pick one):Seminars will begin at 6:30PM and do not repeat.

Violence and Risk Assessment in Clinical Practice (90 minutes)**Ronald Schouten, MD, JD, Sgt. Frederick Cabral, FBI Supervisory Special Agent(America Ballroom, 4th Floor)

Traumatic Brain Injury: A Neuropsychiatric PerspectiveKaloyan S. Tanev, MD(Independence A-B, 4th Floor)

Illuminating the Black Box: Antidepressants, Youth and SuicideDavid H. Rubin, MD(St. George A-B, 3rd Floor)


Sunday, October 25, 2015

7:00 – 7:45AM Continental Breakfast

7:45 – 8:00AM Welcoming Remarks and ReviewDavid H. Rubin, MD

MODULE TOPIC – ADDICTION

8:00 – 9:00AM Tobacco and CocaineA. Eden Evins, MD, MPH

9:00 – 10:00AM Alcohol and OpiatesDomenic A. Ciraulo, MD

10:00 – 10:15AM Coffee Break

MODULE TOPIC – WOMEN’S HEALTH

10:15 – 11:15AM PregnancyLee S. Cohen, MD

11:15 – 12:15PM Post-Partum Mood Disorders Marlene P. Freeman, MD


MODULE TOPIC – ACROSS THE LIFESPAN

1:15 – 2:15PM Pediatric Bipolar Disorder and Mood DisordersJanet Wozniak, MD

2:15 – 3:15PM ADHDJoseph Biederman, MD


3:30 – 4:30PM Rapid Treatments for Psychiatric DisordersCristina Cusin, MD

4:30 – 5:30PM GeriatricsFeyza Marouf, MD

5:30PM Adjourn

Thank you for attending! We hope to see you next year! 40th Annual Psychopharmacology Conference

Boston, MA | October 21 -23, 2016


FACULTY

Jonathan E. Alpert, MD, PhDAssociate Chief of Psychiatry for Clinical Services, Director,Depression Clinical and Research Program, MassachusettsGeneral Hospital, Joyce R. Tedlow Associate Professor ofPsychiatry, Harvard Medical School

Matt T. Bianchi, MD, PhD, MMScChief, Division of Sleep Medicine, Director, Sleep Laboratory,Massachusetts General Hospital

Joseph Biederman, MDChief, Clinical and Research Programs in PediatricPsychopharmacology and Adult ADHD, Director, BresslerProgram for Autism Spectrum Disorders, MassachusettsGeneral Hospital, Professor of Psychiatry, Harvard MedicalSchool

Frederick CabralCommunity Relations Unit Sergeant, Cambridge PoliceDepartment

Joan A. Camprodon, MD, PhD, MPHDirector, Transcranial Magnetic Stimulation (TMS) ClinicalService, Director, Laboratory for Neuropsychiatry andNeuromodulation, Director, Translational Research, Division ofNeurotherapeutics, Attending Physician, Division of BehavioralNeurology, Department of Neurology, Attending Physician,Division of Neuropsychiatry, Department of Psychiatry,Massachusetts General Hospital

Domenic A. Ciraulo, MDDirector of Alcohol Pharmacotherapy Research, Center forAddiction Medicine, Department of Psychiatry, MassachusettsGeneral Hospital

Lee S. Cohen, MDDirector, Center for Women’s Mental Health, Perinataland Reproductive Psychiatry Clinical Research Program,Massachusetts General Hospital, Edmund and Carroll CarpenterProfessor of Psychiatry, Harvard Medical School

Cristina Cusin, MDStaff Psychiatrist, Depression Clinical and Research Program,Massachusetts General Hospital, Assistant Professor, HarvardMedical School

Darin D. Dougherty, MD, MMScDirector, Division of Neurotherapeutics, Department ofPsychiatry, Massachusetts General Hospital, AssociateProfessor of Psychiatry, Harvard Medical School

A. Eden Evins, MD, MPHDirector, Center for Addiction Medicine, Massachusetts GeneralHospital, William Cox Family Associate Professor of Psychiatryin the Field of Addiction Medicine, Harvard Medical School

FBI Supervisory Special Agent

Marlene P. Freeman, MDAssociate Director, Perinatal and Reproductive PsychiatryClinical Research Program, Massachusetts General Hospital,Associate Professor of Psychiatry, Harvard Medical School

Oliver Freudenreich, MD, FAPMMedical Director, MGH Schizophrenia Program, MassachusettsGeneral Hospital, Associate Professor of Psychiatry, HarvardMedical School

David C. Henderson, MDDirector, Schizophrenia Clinical and Research Program,Director, Chester M. Pierce, M.D. Division of Global Psychiatry,Massachusetts General Hospital, Associate Professor ofPsychiatry, Harvard Medical School, Associate Professor ofEpidemiology, Harvard School of Public Health

Michael E. Henry, MDDirector, Somatic Therapy, Medical Director, Bipolar Clinic andResearch Program, Massachusetts General Hospital

Jerrold F. Rosenbaum, MDPsychiatrist-in-Chief, Massachusetts General Hospital, StanleyCobb Professor of Psychiatry, Harvard Medical School

Maurizio Fava, MDDirector, Division of Clinical Research of the MGH ResearchInstitute, Executive Vice Chair, Department of Psychiatry,Executive Director, MGH Clinical Trials Network and Institute,Massachusetts General Hospital, Slater Family Professor ofPsychiatry, Harvard Medical School

Course Directors:

Faculty:

Jodi Gilman, Ph.D.Assistant Professor, Harvard Medical SchoolCenter for Addiction MedicineMassachusetts General Hospital


Michael A. Jenike, MDFounder, OCD Clinic, Massachusetts General Hospital, MedicalDirector, Massachusetts General Hospital/McLean Hospital OCDInstitute, Professor of Psychiatry, Harvard Medical School

Feyza Marouf, MDAssistant Psychiatrist, MGH Geriatric Outpatient Clinic, MGH SiteDirector, Partners Healthcare Geriatric Psychiatry Fellowship

Andrew A. Nierenberg, MDThomas P. Hackett, MD, Endowed Chair in Psychiatry, Director,Bipolar Clinic and Research Program, Associate Director,Depression Clinical and Research Program, Massachusetts GeneralHospital, Professor of Psychiatry, Harvard Medical School

Dost Öngür, MD, PhDChief, Psychotic Disorders Division, McLean Hospital, AssociateProfessor of Psychiatry, Harvard Medical School

Michael W. Otto, PhDDirector, Translational Research Program, Department ofPsychology, Boston University

George I. Papakostas, MDScientific Director, Clinical Trials Network and Institute,Massachusetts General Hospital

Roy H. Perlis, MD, MScDirector, Center for Experimental Drugs and Diagnostics,Department of Psychiatry, Director, Center for Human GeneticResearch, Massachusetts General Hospital, Associate Professor ofPsychiatry, Harvard Medical School

Kerry J. Ressler, MD, PhDChief Scientific Officer, James and Patricia Poitras Chair inPsychiatry, Chief, Division of Depression & Anxiety Disorders,McLean Hospital, Professor of Psychiatry, Harvard Medical School

David H. Rubin, MDDirector of Child and Adolescent Psychiatry, Residency Training,Director, Postgraduate Medical Education, Massachusetts GeneralHospital

Ronald Schouten, MD, JDDirector, Law & Psychiatry Service, Massachusetts GeneralHospital, Associate Professor of Psychiatry, Harvard MedicalSchool

Naomi M. Simon, MD, MScChief Medical Officer, Red Sox Foundation and MassachusettsGeneral Hospital Home Base Program, Director, Center forAnxiety & Traumatic Stress Disorders, Director, ComplicatedGrief Program, Massachusetts General Hospital, Professor ofPsychiatry, Harvard Medical School

Theodore A. Stern, MDChief, Avery D. Weisman Psychiatric Consultation Service,Director, Office for Clinical Careers, Massachusetts GeneralHospital, Ned H. Cassem Professor of Psychiatry in the field ofPsychosomatic Medicine/Consultation, Harvard Medical School

Kaloyan S. Tanev, MDDirector of Clinical Neuropsychiatry Research, MassachusettsGeneral Hospital, Assistant Professor of Psychiatry, HarvardMedical School

Janet Wozniak, MDDirector, Quality and Safety, Department of Psychiatry, Director,Child and Adolescent Outpatient Service, Director, PediatricBipolar Disorder Clinical and Research Program, MassachusettsGeneral Hospital, Associate Professor of Psychiatry, HarvardMedical School

Albert S. Yeung, MD, ScDDirector of Primary Care Research, Depression Clinical andResearch Program, Massachusetts General Hospital, AssociateProfessor of Psychiatry, Harvard Medical School

Lisa M. Zakhary, MD, PhDStaff Psychiatrist, OCD and Related Disorders Program, PrimaryCare Psychiatry, Massachusetts General Hospital, Instructor inPsychiatry, Harvard Medical School


FACULTY DISCLOSURE STATEMENTS

In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council onContinuing Medical Education, speakers have been asked to disclose any relationship they have to companies producingpharmaceuticals, medical equipment, devices, etc. that might be germane to the content of their lectures. Such disclosureis not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information thatmight be of potential importance to their evaluation of a given talk. In addition, faculty have been asked to describe any “offlabel” uses of pharmaceutical products and devices.

1. The following speakers and/or planners and/or their spouses/ partners have reported no relevant financialrelationship with a commercial interest:

Planners:Jane Pimental, MPHDavid H. Rubin, MD (Reviewer/Speaker)

Speakers:Frederick CabralJoan A. Camprodon, MD, PhD, MPHDomenic A. Ciraulo, MDCristina Cusin, MDFBI Supervisory Special Agent Jodi Gilman, PhDMichael A. Jenike, MDFeyza Marouf, MDDost Öngür, MD, PhDRonald Schouten, MD, JDKaloyan S. Tanev, MDAlbert S. Yeung, MD, ScDLisa M. Zakhary, MD, PhD

2. The following speakers and/or planners and/or their spouses/ partners have reported relevant financialrelationships with commercial interests:

Jonathan E. Alpert, MD, PhDSpeaker’s Honoraria: American Society of Clinical Psychopharmacology, American Psychiatric Association,Janssen, Nevada Psychiatric Association, North Shore Medical Center, Psicofarma, Reed Medical Education,University of LouisvilleRoyalties: Belvoir Publishing, Marcel Dekker, Institut la Conference HippocrateConsultant fees: PamLab LLC, Luye PharmaceuticalsResearch support: Abbott Labs, Alkermes, Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb,Cephalon, Eli Lilly & Co., Forest Pharmaceuticals, GlaxoSmithKline, J&J Pharmaceuticals, Lichtswer Pharma,Novartis, Organon, PamLab LLC, Pharmavite, Roche Laboratories, Solvay Pharma, Sanofi/Synthelabo, Wyeth-Ayerst

Matt T. Bianchi, MD, PhD, MMScFunding: MGH Neurology Department, Harvard Clinical Investigator Fellowship (‘09-11), CIMIT YoungClinician Award (‘11-13), Harvard Catalyst KL-2 (‘11-13), Milton Foundation (‘14-15), MGH-MIT Grand Challenge(‘14-15), Department of Defense (‘15-’16)Patent Pending: Rest DevicesAdvisory Board: ForamisTravel Funds: ServierResearch: Insomnisolv, MC10Consultant: GrandRounds, Insomnisolv, MC10Dr. Bianchi also provides Expert Testimony


Joseph Biederman, MDResearch Support: DOD, FDA, AACAP , Alcobra, Forest Research Institute, Ironshore, Lundbeck, MagceuticsInc., Merck, PamLab, Pfizer, Shire Pharmaceuticals Inc., SPRITES, Sunovion, Vaya Pharma/Enzymotec, andNIH.Royalties paid to the Department of Psychiatry at MGH, for a copyrighted ADHD rating scale used forADHD diagnoses: Ingenix, Prophase, Shire, Bracket Global, Sunovion, and TheravancePatents: US Patent Application (Provisional Number #61/233,686) through MGH corporate licensing, on a methodto prevent stimulant abuse.

Lee S. Cohen, MDResearch Support: National Pregnancy Registry for Atypical Antipsychotics: AstraZeneca; Bristol-MyersSquibb/Otsuka; Ortho-McNeil Janssen; Sunovion Pharmaceuticals, Inc.; Other research support: Cephalon, Inc.;National Institute on Aging; National Institutes of Health; National Institute of Mental Health; Takeda/LundbeckAdvisory/Consulting: JDS Therapeutics LLC

Darin D. Dougherty, MD, MMScResearch Support: Cyberonics, Medtronic, Eli Lilly, RocheHonoraria: Insys, Johnson & Johnson

A. Eden Evins, MD, MPHResearch Support (to institution): Forum Pharmaceuticals, Pfizer Inc.Advisory Board: Reckitt Benckizer

Maurizio Fava, MDAdvisory Board/Consultant: Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; AmarinPharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOMETherapeutics; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; BiovailCorporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; CNS Response,Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; DinipponSumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly andCompany; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience,Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; GenOmind, LLC;GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.;Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; LabopharmInc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.;Naurex, Inc.; Nestle Health Sciences; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; NovartisAG;Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab, LLC.;Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; PrexaPharmaceuticals, Inc.; PPD; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals,Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; SupernusPharmaceuticals, Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; TetragenexPharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals,Inc.Speaking/Publishing: Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; AmericanSociety of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH;Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company;Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGHPsychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; UnitedBioSource,Corp.; Wyeth-Ayerst Laboratories.Research Support: Abbot Laboratories; Alkermes, Inc.; American Cyanamid;Aspect Medical Systems;


AstraZeneca; Avanir Pharmaceuticals; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma;Cephalon; Clintara, LLC; Covance; Covidien; Eli Lilly and Company;EnVivo Pharmaceuticals, Inc.; EuthymicsBioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical ResearchInstitute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation;Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals;Lundbeck Inc.; MedAvante; Methylation Sciences Inc; National Alliance for Research on Schizophrenia &Depression (NARSAD); National Center for Complementary and Alternative Medicine (NCCAM); NationalInstitute of Drug Abuse (NIDA); National Institute of Mental Health (NIMH); Neuralstem, Inc.; Novartis AG;Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates.,Inc.; Pharmavite® LLC;PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCTLogic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals,Inc.; Stanley Medical Research Institute (SMRI); Synthelabo; Wyeth-Ayerst LaboratoriesStock/Other Financial Options: Equity Holdings: Compellis; PsyBrain, Inc.Royalty/patent, other income: Patents for Sequential Parallel Comparison Design (SPCD), licensed by MGHto Pharmaceutical Product Development, LLC (PPD); and patent application for a combination of Ketamine plusScopolamine in Major Depressive Disorder (MDD), licensed by MGH to Biohaven.Copyright for the MGH Cognitive & Physical Functioning Questionnaire (CPFQ), Sexual Functioning Inventory(SFI), Antidepressant Treatment Response Questionnaire (ATRQ), Discontinuation-Emergent Signs & Symptoms(DESS), Symptoms of Depression Questionnaire (SDQ), and SAFER; Lippincott, Williams & Wilkins; WolkersKluwer; World Scientific Publishing Co. Pte.Ltd.

Marlene P. Freeman, MDResearch Funding (investigator initiated studies): TakedaAdvisory Boards: Takeda, Sunovion, JDS TherapeuticsCME/Honorarium for Medical Editing: GOED newsletter

Oliver Freudenreich, MD, FAPMResearch Grant: Psychogenics, ForumHonoraria: Global Medical Education, Med-IQ, Oakstone Medical EducationConsultant: Optimal Medicine, Beacon Health StrategiesRoyalties: UpToDate

David C. Henderson, MDResearch Grant: Forum Pharmaceuticals, NorvartisSpeaker Fee: Global Psychiatry CME, Mclean HospitalAdvisory Board: Reckitt Benckiser

Michael E. Henry, MDResearch Grant: Forest PharmaceuticalsSpouse Salary: Roche Pharmaceuticals

Andrew A. Nierenberg, MDConsultant: Abbott Laboratories, Astra Zeneca, Basilea, BrainCells Inc., Bristol-Myers Squibb, Cephalon,Clintara, Corcept, Eli Lilly & Co., Forest, Genaissance, Genentech, GlaxoSmithKline, Innapharma, JanssenPharmaceutica, Jazz Pharmaceuticals, Lundbeck, Medavante, Merck, Novartis, PamLabs, PGx Health, Pfizer,Roche, Sepracor, Schering-Plough, Shire, Somerset, Sunovion, Takeda, Targacept, TevaStockholder: Appliance Computing, Inc. (MindSite); Brain Cells, Inc., MedavanteGrant Support: AFSP, AHRQ, Bristol-Myers Squibb, Cederroth, Cyberonics, Forest Pharmaceuticals,GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Eli Lilly, NARSAD, NIMH, PCORI, Pfizer, Shire,Stanley Foundation, Takeda, Wyeth-AyerstOther Income: MBL Publishing for past services as Editor-in-chief of CNS Spectrums; Slack Inc. for services asAssociate Editor of Psychiatric Annals; Editorial Board, Mind Mood Memory, Belvior PublicationsPatents and Copyrights: Copyright joint ownership with MGH for Structured Clinical Interview for MADRS andClinical Positive Affect Scale


Honoraria: ADURS, Brain and Behavior Foundation Colvin Prize, University of :Pisa, University of Wisconsin atMadison, University Texas Southwest at Dallas, Health New England and Harold Grinspoon Charitable Foundationand Eli Lilly and AstraZeneca, American Society for Clinical Psychopharmacology and Zucker Hillside Hospitaland Forest and Janssen, Brandeis University, International Society for Bipolar Disorder

Michael W. Otto, PhDGrant Support: NIMH, NIDARoyalties: Oxford University Press, Routledge

George I. Papakostas, MDConsultant: Abbott Laboratories, AstraZeneca PLC, Avanir Pharmaceuticals, Brainsway Ltd., Bristol-MyersSquibb Co., Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., Genentech, Inc., GlaxoSmithKline, Evotec AG, H.Lundbeck A/S, Inflabloc Pharmaceuticals, Janssen Global Services LLC, Jazz Pharmaceuticals, Johnson & JohnsonCompanies, Novartis Pharma AG, One Carbon Therapeutics, Inc., Otsuka Pharmaceuticals, PAMLAB LLC, PfizerInc., Pierre Fabre Laboratories, Ridge Diagnostics (formerly known as Precision Human Biolaboratories), ShirePharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos, Inc., and Wyeth,Inc.Honoraria: Abbott Laboratories, Astra Zeneca PLC, Avanir Pharmaceuticals, Bristol-Myers SquibbCo., Brainsway Ltd., Cephalon Inc., Dey Pharma, L.P., Eli Lilly Co., Evotec AG, Forest Pharmaceuticals,GlaxoSmithKline, Inflabloc Pharmaceuticals, Jazz Pharmaceuticals, H. Lundbeck A/S, Medichem Pharmaceuticals,Inc., Novartis Pharma AG, Otsuka Pharmaceuticals, PAMLAB LLC, Pfizer, Pierre Fabre Laboratories, RidgeDiagnostics, Shire Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company LTD, Theracos,Inc., Titan Pharmaceuticals, and Wyeth Inc.Research Support: AstraZeneca PLC, Bristol-Myers Squibb Co., Forest Pharmaceuticals, the NationalInstitute of Mental Health, PAMLAB LLC, Pfizer Inc., Ridge Diagnostics (formerly known as Precision HumanBiolaboratories), Sunovion Pharmaceuticals, and Theracos, Inc.Speaker’s Bureau: Dr. Papakostas has served (not currently) on the speaker’s bureau for Bristol-Myers Squibb Co.and Pfizer, Inc.

Roy H. Perlis, MD, MScScientific Advisory Board: Psybrain, GenomindConsultation: Genomind, RID Ventures, Perfect HealthAdvisor: Perfect Health

Jerrold F. Rosenbaum, MDEquity Interest: MedavanteEquity Interest: Founder: PsyBrain

Kerry J. Ressler, MD, PhDFounding Member: Extinction Pharmaceuticals/ Therapade Technologies (received no equity or income from thisrelationship within the last 3 years).Patents: D-cycloserine and psychotherapy, targeting PACAP for extinction, targeting tachykinin 2 for prevention offear, targeting angiotensin to improve extinction of fear.Funding: NIMH, HHMI, NARSAD, Burroughs Wellcome Foundation


Naomi M. Simon, MD, MScResearch Grants: American Foundation for Suicide Prevention, Department of Defense, Highland StreetFoundation, NIHSpeaking/CME/Consulting: Pfizer PharmaceuticalsEquity (Spouse): Dandreon, G Zero, Gatekeeper

Theodore A. Stern, MDSalary: Academy of Psychosomatic Medicine (Editor in Chief Psychosomatics)Royalties: ElsevierHonoraria: Psychiatric Annals

Janet Wozniak, MDResearch funding: Merck/Schering-PloughConsultation Fees (Spouse): Associated Professional Sleep Societies, Gerson Lerman Group, Summer StreetPartners, UCB, Cantor ColburnRoyalties (Spouse): Cambridge University Press

RESOLUTION OF CONFLICT OF INTEREST (COI)McLean Hospital has implemented a process to resolve COI for each CME activity. In order to help ensure contentobjectivity, independence, fair balance and ensure that the content is aligned with the interest of the public, McLeanHospital has resolved the conflict by External Content Review.

* “Something of value” refers to an equity position, receipt of royalties, consultantship, funding by a research grant,receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficientreason for disclosure, in keeping with the spirit of the stated policy.


FACULTY NAME TOPIC DAY AND TIMEAndrew A. Nierenberg, MD Bipolar Disorder and

DepressionFriday, October 23, 9:15am – 10:15am

Naomi M. Simon, MD, MSc Anxiety and PTSD Friday, October 23, 3:15pm – 4:15pm

Oliver Freudenreich, MD, FAPM Psychosis Saturday, October 24, 9:00am – 10:00am

John D. Matthews, MD Depression and InpatientPsychiatry

Saturday, October 24, 1:00pm – 2:00pm

Theodore A. Stern, MD Consult Psychiatry Saturday, October 24, 4:00pm – 5:00pm

Marlene P. Freeman, MD Women’s Health Sunday, October 25, 10:15am – 11:15am

Lee S. Cohen, MD Women’s Mental Health Sunday, October 25, 11:15am – 12:15pm

Cristina Cusin, MD Rapid Treatments Sunday, October 25, 2:30pm – 3:30pm

PSYCHOPHARMACOLOGYCURBSIDE CONSULTANTS SCHEDULE

OCTOBER 22 - 25, 2015


Jodi Gilman, PhD

Matt T. Bianchi, MD, PhD, MMSc

162636 rp graphics text

Documents